ZIMLABPharmaceuticals
Zim Laboratories Ltd — PE Ratio & Valuation Analysis
₹60.26
-0.45%
Current P/E54.11xPrice to earnings
Industry P/E31.77xSector average
4Y Avg P/E28.7x88.5% above avg
⚠️
70.3% Premium to Industry
ZIMLAB P/E 54.11x vs sector avg 31.77x
📊
Historical PE Ratio
| Year | EPS (₹) | Year-end Price | PE Ratio |
|---|---|---|---|
| 2025 | ₹2.50 | ₹72 | 28.9x |
| 2024 | ₹3.54 | ₹108 | 30.4x |
| 2023 | ₹5.01 | ₹115 | 23x |
| 2022 | ₹2.99 | ₹97 | 32.5x |
PE = Year-end closing price ÷ Diluted EPS. Source: NSE/BSE filings.
💡
Understanding Zim Laboratories Ltd Valuation
Zim Laboratories Ltd (ZIMLAB) currently trades at 54.11x earnings. The Pharmaceuticals sector average PE is 31.77x. ZIMLAB commands a premium, reflecting high growth expectations. Historically, ZIMLAB has traded at an average PE of 28.7x — it is currently above that level. Always evaluate PE alongside earnings growth (PEG ratio), return on equity, debt levels and business quality. A lower PE isn't always better. Educational data only — not investment advice.
ROE
4.96%
Dividend Yield
0.00%
More on Zim Laboratories Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.